Q-omics provides the consensus-scored MTRNR2L2 profile across patient tissues and cancer cell-line models. MTRNR2L2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MTRNR2L2 is differentially expressed in 3, with the highest sampling consensus in UCEC. Additionally, MTRNR2L2 RNA expression shows 11,848 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, and ACC as cancer lineages where MTRNR2L2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTRNR2L2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTRNR2L2 survival associations across molecular data types. MTRNR2L2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTRNR2L2 RNA expression–survival associations across cancer types. High MTRNR2L2 expression shows unfavorable associations in UCEC, BRCA and KIRC, but favorable associations in BLCA, ACC and HNSC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for MTRNR2L2 RNA expression.
This table summarizes MTRNR2L2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for MTRNR2L2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTRNR2L2 shows lower tumor expression in UCEC, COAD and HNSC. The UCEC box plot shows higher MTRNR2L2 RNA expression in normal versus tumor tissue (log2 FC = −0.769, t-test p = .012).
This table shows molecular features associated with MTRNR2L2 in patient tissues and cancer cell lines. In patient samples, MTRNR2L2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
